Bridgebio Pharma Stock Analysis

BridgeBio Stock Analysis Notes

About 100.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.05. BridgeBio Pharma recorded a loss per share of 4.21. The entity had not issued any dividends in recent years. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company was founded in 2015 and is headquartered in Palo Alto, California. Bridgebio Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 576 people. For more info on BridgeBio Pharma please contact the company at 650 391 9740 or go to https://bridgebio.com.

BridgeBio Pharma Investment Alerts

BridgeBio Pharma Upcoming and Recent Events

BridgeBio Largest EPS Surprises

View All Earnings Estimates

BridgeBio Pharma Environmental, Social, and Governance (ESG) Scores

BridgeBio Stock Institutional Investors

Note, although BridgeBio Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

BridgeBio Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 12.07 B.

BridgeBio Profitablity

The company has Profit Margin (PM) of (2.25) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.13) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.13.

Management Efficiency

BridgeBio Pharma has return on total asset (ROA) of (0.4348) % which means that it has lost $0.4348 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.8967) %, meaning that it created substantial loss on money invested by shareholders. BridgeBio Pharma's management efficiency ratios could be used to measure how well BridgeBio Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 3rd of November 2025, Return On Equity is likely to grow to 0.39, while Return On Tangible Assets are likely to drop (0.63). At this time, BridgeBio Pharma's Asset Turnover is very stable compared to the past year.

Technical Drivers

As of the 3rd of November, BridgeBio Pharma shows the Downside Deviation of 2.71, mean deviation of 2.2, and Risk Adjusted Performance of 0.0999. BridgeBio Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

BridgeBio Pharma Price Movement Analysis

BridgeBio Pharma Insider Trading Activities

BridgeBio Pharma Outstanding Bonds

BridgeBio Pharma Predictive Daily Indicators

BridgeBio Pharma Corporate Filings

BridgeBio Pharma Forecast Models

BridgeBio Pharma's time-series forecasting models are one of many BridgeBio Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BridgeBio Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how BridgeBio Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BridgeBio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as BridgeBio Pharma. By using and applying BridgeBio Stock analysis, traders can create a robust methodology for identifying BridgeBio entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. BridgeBio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. BridgeBio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

BridgeBio Pharma stock analysis indicators help investors evaluate how BridgeBio Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading BridgeBio Pharma shares will generate the highest return on investment. By understating and applying BridgeBio Pharma stock analysis, traders can identify BridgeBio Pharma position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.